- $717.32m
- $569.96m
Brief: Candel Therapeutics Receives FDA Fast Track Designation For Can-2409 In Non-Small Cell Lung Cancer
U.S. RESEARCH ROUNDUP- Cintas, Stryker, Zimmer Biomet Holdings
Brief: Candel Therapeutics Reports Q4 Loss Per Share Of $0.18
Brief: Candel Therapeutics Changes Primary Endpoint Of Its Phase 2 Clinical Trial Of CAN-2409
U.S. RESEARCH ROUNDUP- Autozone, Nike, Sachem Capital
Brief: Candel Therapeutics Research And Development Day Presentations Spotlight Its Advanced Pipeline And Capabilities To Develop Novel Viral Immunotherapies For Patients With Cancer
Brief: Candel Therapeutics Announces Oral Presentation Of Updated Data From Its Phase 1 Clinical Trial Of CAN-3110
U.S. RESEARCH ROUNDUP-Expensify, NVIDIA, Signature Bank
Brief: Candel Therapeutics Partners With The University Of Pennsylvania’S Center For Cellular Immunotherapies To Study Combinations Of Novel Viral Immunotherapy And Car-T Cell Therapy In Solid Tumor Models
Brief: Candel Receives Orphan Drug Designation From European Medicines Agency For CAN-2409 In Glioma
Brief: Candel Therapeutics Inc Names Jason Amello As Chief Financial Officer
U.S. RESEARCH ROUNDUP- Carvana, McKesson, Nektar Therapeutics
Brief: Candel Therapeutics Inc Files For Mixed Shelf Of Up To $200 Million – SEC Filing
Brief: Candel Therapeutics Inc Reports Q2 Net Loss Per Share Of $0.14
NASDAQ RESUMED AT 09:38 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:31 AM
Brief: Candel Therapeutics Announces Release Of Initial Data On Can-2409
U.S. RESEARCH ROUNDUP-First Solar, Henry Schein, Petiq
Brief: Candel Therapeutics Reports First Quarter 2022 Financial Results